View Post

Mustang Bio Announces $9.28 Million Grant to Fund Phase 1 Trial of CAR T Therapy MB-103 in HER2-Positive Breast Cancer with Brain Metastases

In Clinical Trials by Barbara Jacoby

From: Mustang Bio, Inc. (“Mustang”) (MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases, today announced that City of Hope has received a $9.28 million grant from the California Institute for Regenerative Medicine (CIRM) to fund an ongoing Phase 1 …